evaluation of the efficacy and the safety of intralesional cidofovir for recurrent laryngeal papillomatosis

evaluation of the efficacy and the safety of intralesional cidofovir for recurrent laryngeal papillomatosis - intralesional cidofovir for recurrent laryngeal papillomatosis

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010967

Enrollment

Registered

2013-06-17

Start date

2013-06-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

human papillomavirus positive recurrent laryngeal papillomatosis

Interventions

intralesional cidofovir

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: human papillomavirus positive recurrent laryngeal papillomatosis

Exclusion criteria

Exclusion criteria: renal dysfunction

Design outcomes

Primary

Measure	Time frame
Tumor reduction / disappearance rate and time, adverse events	—

Countries

Japan

Contacts

Public ContactDaisuke Sano

Yokohama City University School of Medicine Department of Otorhinolaryngology, Head and Neck Surgery

dsano@yokohama-cu.ac.jp045-787-2687

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026